News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Jul 28, 2021 9:40 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Jun 14, 2021
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
Jun 11, 2021
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
May 20, 2021
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
Upcoming Events
Jun 11, 2021
8:00 AM EDT
Forma Therapeutics Virtual Investor Event
Learn more
Jun 2, 2021
11:00 AM EDT
Jefferies Virtual Healthcare Conference
Learn more
May 21, 2021
Oppenheimer Rare & Orphan Disease Summit
Learn more